A Phase 2 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis (PMO), sponsored by Amgen. Completed at 27 sites in Japan. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-25.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 7th largest by enrollment, is one of 3 that started in 2012, is one of 3 in phase 2, and was the 5th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2012.
This study's enrollment of 252 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2012, is one of 4 in phase 2, and was the 18th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ambulatory, Japanese women with osteoporosis (defined as bone mineral density T-score of ≤ -4.00 at the lumbar spine or BMD T-score of ≤ -3.50 at the total hip, or femoral neck)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
Drug: Placebo
Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
Drug: Romosozumab
Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
Drug: Romosozumab
Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
Drug: Romosozumab
Administered by subcutaneous injection
Also known as: AMG 785, EVENITY™
Administered by subcutaneous injection
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 12 months
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 6 months
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 6 months
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip
Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 12 months
Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 6 months
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
Time frame: Baseline and 12 months
Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)
Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)
Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Percent Change From Baseline in Osteocalcin
Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)
Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Area Under the Curve Through Month 12 of P1NP
Time frame: Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.
This study was conducted at 24 centers in Japan. The first participant was enrolled on 12 October 2012 and the last participant enrolled on 15 October 2013.
| Milestone | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Started | 63 | 63 | 63 | 63 |
| Received treatment | 63 | 63 | 63 | 63 |
| Completed first 12 months of study | 59 | 56 | 63 | 59 |
| Completed | 59 | 55 | 62 | 59 |
| Not completed | 4 | 8 | 1 | 4 |
| Withdrew: Withdrawal by subject | 4 | 7 | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine | 0.9 (0.1 to 1.8) | 8.4 (7.6 to 9.3) | 13.3 (12.1 to 14.5) | 16.9 (15.5 to 18.4) |
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine | 1.2 (0.5 to 1.9) | 6.5 (5.7 to 7.2) | 10.2 (9.2 to 11.2) | 13.1 (11.7 to 14.5) |
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip | 0.6 (-0.0 to 1.3) | 1.2 (0.5 to 2.0) | 2.3 (1.7 to 2.9) | 3.2 (2.5 to 3.9) |
Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip | 0.6 (-0.0 to 1.3) | 2.1 (1.4 to 2.8) | 3.2 (2.6 to 3.9) | 4.7 (4.0 to 5.5) |
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck | 0.6 (-0.1 to 1.4) | 1.0 (0.1 to 1.8) | 1.9 (1.0 to 2.9) | 3.3 (2.1 to 4.4) |
Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck | 0.3 (-0.6 to 1.2) | 1.9 (1.0 to 2.7) | 2.9 (2.1 to 3.8) | 3.8 (2.7 to 4.9) |
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 1 | -2.5 ± 9.0 | 43.4 ± 24.0 | 65.9 ± 25.7 | 81.5 ± 34.6 |
| Month 1 | -5.7 ± 22.1 | 32.2 ± 22.9 | 79.8 ± 41.7 | 101.6 ± 41.1 |
| Month 2 | -10.9 ± 18.5 | -0.7 ± 18.4 | 34.6 ± 38.2 | 59.8 ± 40.5 |
| Month 3 | -11.5 ± 20.3 | -13.1 ± 18.3 | 14.9 ± 32.2 | 25.5 ± 33.4 |
| Month 6 | -8.9 ± 23.3 | -16.8 ± 26.0 | -2.7 ± 28.0 | 2.4 ± 24.8 |
| Month 9 | -2.1 ± 32.0 | -16.9 ± 31.3 | -9.1 ± 30.9 | -4.0 ± 31.5 |
| Month 12 | 4.6 ± 37.9 | -11.1 ± 29.8 | -16.2 ± 27.4 | -13.1 ± 28.1 |
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 1 | 11.9 ± 27.8 | -28.0 ± 25.8 | -32.1 ± 32.8 | -42.0 ± 25.4 |
| Month 1 | 14.9 ± 40.2 | -18.0 ± 34.3 | -8.0 ± 53.9 | -24.6 ± 30.5 |
| Month 2 | 14.1 ± 41.6 | -2.3 ± 48.4 | 14.9 ± 67.8 | 0.1 ± 49.1 |
| Month 3 | 16.1 ± 49.0 | -5.5 ± 48.3 | 28.9 ± 84.1 | 8.1 ± 53.8 |
| Month 6 | 13.6 ± 49.8 | -10.8 ± 52.2 | 3.2 ± 71.8 | -13.4 ± 40.6 |
| Month 9 | 12.6 ± 56.6 | -13.2 ± 53.0 | -8.0 ± 55.7 | -15.3 ± 44.8 |
| Month 12 | 35.4 ± 81.7 | -4.1 ± 47.2 | 2.1 ± 73.5 | -10.5 ± 53.8 |
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 1 | 2.6 ± 18.1 | 6.5 ± 12.6 | 7.9 ± 17.0 | 5.5 ± 14.5 |
| Month 1 | -3.8 ± 12.7 | 26.5 ± 20.4 | 51.2 ± 31.9 | 66.4 ± 31.3 |
| Month 2 | -7.0 ± 13.4 | 13.7 ± 15.1 | 39.3 ± 31.6 | 48.9 ± 31.6 |
| Month 3 | -7.2 ± 16.8 | 4.9 ± 17.5 | 28.4 ± 29.7 | 27.5 ± 22.3 |
| Month 6 | -10.3 ± 15.9 | -5.5 ± 18.8 | 10.6 ± 24.7 | 9.3 ± 19.2 |
| Month 9 | -8.4 ± 18.2 | -6.8 ± 22.5 | -0.9 ± 24.0 | -1.3 ± 18.9 |
| Month 12 | -6.8 ± 20.6 | -8.6 ± 21.8 | -9.4 ± 22.1 | -8.9 ± 17.9 |
| percent change | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Week 1 | 1.6 ± 13.4 | 14.0 ± 14.5 | 17.0 ± 16.4 | 20.1 ± 17.9 |
| Month 1 | -0.5 ± 22.1 | 23.0 ± 19.9 | 51.3 ± 27.6 | 66.2 ± 31.9 |
| Month 2 | -7.8 ± 16.9 | 8.7 ± 20.8 | 31.8 ± 27.9 | 55.1 ± 31.0 |
| Month 3 | -9.5 ± 16.3 | -2.8 ± 14.9 | 23.5 ± 26.5 | 39.6 ± 33.2 |
| Month 6 | -6.6 ± 20.5 | -9.0 ± 19.0 | 3.1 ± 21.6 | 13.2 ± 26.8 |
| Month 9 | -7.0 ± 20.5 | -10.7 ± 21.7 | -2.6 ± 25.3 | 3.5 ± 23.8 |
| Month 12 | -6.3 ± 22.7 | -13.2 ± 19.9 | -13.7 ± 23.3 | -9.3 ± 21.4 |
| ug*month/L | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Area Under the Curve Through Month 12 of P1NP | 554.5 (523.0 to 585.9) | 539.2 (506.4 to 572.0) | 638.5 (607.9 to 669.2) | 708.3 (676.6 to 740.0) |
Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/63 (7.9%) | 20/63 (31.7%) |
| Romosozumab 70 mg | — | 6/63 (9.5%) | 33/63 (52.4%) |
| Romosozumab 140 mg | — | 3/63 (4.8%) | 29/63 (46%) |
| Romosozumab 210 mg | — | 2/63 (3.2%) | 32/63 (50.8%) |
| Event | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/63 | 0/63 | 1/63 | 0/63 |
| Angina pectorisCardiac disorders | 1/63 | 0/63 | 0/63 | 0/63 |
| Angina unstableCardiac disorders | 0/63 | 0/63 | 0/63 | 1/63 |
| Atrioventricular block second degreeCardiac disorders | 0/63 | 1/63 | 0/63 | 0/63 |
| Coronary artery stenosisCardiac disorders | 0/63 | 1/63 | 0/63 | 0/63 |
| Ventricular extrasystolesCardiac disorders | 1/63 | 0/63 | 0/63 | 0/63 |
| CataractEye disorders | 0/63 | 0/63 | 0/63 | 1/63 |
| Vitreous haemorrhageEye disorders | 0/63 | 0/63 | 0/63 | 1/63 |
| Large intestine polypGastrointestinal disorders | 0/63 | 0/63 | 1/63 | 0/63 |
| CholelithiasisHepatobiliary disorders | 0/63 | 1/63 | 0/63 | 0/63 |
| Event | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/63 | 17/63 | 17/63 | 20/63 |
| ContusionInjury, poisoning and procedural complications | 5/63 | 6/63 | 2/63 | 1/63 |
| Back painMusculoskeletal and connective tissue disorders | 4/63 | 2/63 | 5/63 | 3/63 |
| EczemaSkin and subcutaneous tissue disorders | 1/63 | 4/63 | 5/63 | 1/63 |
| HypertensionVascular disorders | 2/63 | 1/63 | 5/63 | 1/63 |
| Abdominal pain upperGastrointestinal disorders | 4/63 | 0/63 | 1/63 | 3/63 |
| Dental cariesGastrointestinal disorders | 1/63 | 4/63 | 3/63 | 2/63 |
| Upper respiratory tract infectionInfections and infestations | 2/63 | 1/63 | 4/63 | 0/63 |
| Ligament sprainInjury, poisoning and procedural complications | 4/63 | 1/63 | 0/63 | 3/63 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/63 | 0/63 | 2/63 | 4/63 |
| Age, Continuous(years) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Mean | 67.8 ± 7.2 | 66.5 ± 6.3 | 68.4 ± 6.0 | 68.3 ± 5.9 | 67.7 ± 6.4 |
| Age, Customized(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| < 65 years | 27 | 30 | 18 | 18 | 93 |
| ≥ 65 to < 75 years | 22 | 22 | 34 | 34 | 112 |
| ≥ 75 years | 14 | 11 | 11 | 11 | 47 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Female | 63 | 63 | 63 | 63 | 252 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Asian | 63 | 63 | 63 | 63 | 252 |
| Lumbar Spine Bone Mineral Density (BMD) T-score(T-score) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Mean | -2.69 ± 0.52 | -2.73 ± 0.57 | -2.65 ± 0.66 | -2.72 ± 0.42 | -2.70 ± 0.54 |
| Total Hip BMD T-score(T-score) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Mean | -2.00 ± 0.60 | -1.97 ± 0.57 | -1.85 ± 0.68 | -1.95 ± 0.65 | -1.94 ± 0.63 |
| Femoral Neck BMD T-score(T-score) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Mean | -2.31 ± 0.47 | -2.27 ± 0.53 | -2.28 ± 0.65 | -2.32 ± 0.59 | -2.29 ± 0.56 |
| Serum Procollagen Type 1 N-telopeptide (P1NP)(μg/L) | Placebo | Romosozumab 70 mg | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|---|---|
| Median | 52.4 (41.9 to 62.9) | 51.9 (40.5 to 59.8) | 47.6 (37.7 to 54.9) | 50.9 (38.0 to 59.1) | 50.5 (38.6 to 59.4) |
3 further baseline measures are reported on the registry.
Ran from Oct 2012 to primary completion in Oct 2014, 23 months.
Results were first posted in Mar 2019, 4 years 5 months after primary completion. A results delay was requested in Sep 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →